Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

With the increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and thus its socioeconomic impact are growing. Increasing knowledge over the last years about the pathomechanisms involved in AD allow for the development of specific treatment strategies aimed at slowing down or even preventing neuronal death in AD. However, this requires also that (1) AD can be diagnosed with high accuracy, because non-AD dementias would not benefit from an AD-specific treatment; (2) AD can be diagnosed in very early stages when any intervention would be most effective; and (3) treatment efficacy can be reliably and meaningfully monitored. Although there currently is no ideal biomarker that would fulfill all these requirements, there is increasing evidence that a combination of currently existing neuroimaging and cerebrospinal fluid (CSF) and blood biomarkers can provide important complementary information and thus contribute to a more accurate and earlier diagnosis of AD. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is exploring which combinations of these biomarkers are the most powerful for diagnosis of AD and monitoring of treatment effects.

What this study adds

Evidence grade: Not rated

Argues that earlier and more accurate Alzheimer's diagnosis may come from combining imaging, spinal fluid and blood biomarkers. It describes the Alzheimer's Disease Neuroimaging Initiative (ADNI) as exploring which combinations work best for diagnosis and for tracking treatment effects.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., et al. (2005). Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2005.06.003

Vancouver

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust WJ, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer s & Dementia. 2005. doi:10.1016/j.jalz.2005.06.003. PMID: 17476317.

BibTeX

@article{mueller2005-17476317,
  author  = {Mueller, Susanne G. and Weiner, Michael Walter and Thal, Leon J. and Petersen, Ronald Carl and Jack, Clifford R. and Jagust, William J. and Trojanowski, John Q. and Toga, Arthur W. and Beckett, Laurel A.},
  title   = {{Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)}},
  journal = {Alzheimer s \& Dementia},
  year    = {2005},
  doi     = {10.1016/j.jalz.2005.06.003},
  pmid    = {17476317},
  url     = {https://doi.org/10.1016/j.jalz.2005.06.003}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Why it matters

Argues that earlier and more accurate Alzheimer's diagnosis may come from combining imaging, spinal fluid and blood biomarkers. It describes the Alzheimer's Disease Neuroimaging Initiative (ADNI) as exploring which combinations work best for diagnosis and for tracking treatment effects.

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 51 of the 95 points it could be judged on, which is 54 of 100. Total 54 of 100.51 of the 95 points we could judge = 54 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 51 of the 95 points we could judge it on, which is 54 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2005 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,240 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 53.9 citations a year over 23 year(s) since 2005
Impact for its field and year 3 / 6 Cited 6.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 4 / 4 Cited 260 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Laurel A. Beckett: h-index 116 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, Berkeley: institution h-index 2,012 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17476317)
Free to read 2 / 2 Free to read
Points 51 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 95 points we could judge it on is 54 out of 100.
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Biomarkers from nearby years

Also in Biomarkers

136 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →